Table 3.
Cardiovascular Risk and Comorbidities in MDI‐HTN and the Reference Population
| Medical Indices | Reference (n=30) | MDI‐HTN (n=55) |
|---|---|---|
| Target organ damage | ||
| LVH, No. (%) | 14 (47) | 30 (55) |
| Renal indices | ||
| sCr, μmol/L | 91±35 | 87±31 |
| eGFR, mL/min | 70±19 | 74±19 |
| Lipid indices | ||
| TC:HDL ratio | 3.4±1.2 | 3.6±0.9 |
| Comorbidities, No. (%) | ||
| GERD | 3 (10) | 23 (42) |
| Anxiety disorder | 1 (3) | 9 (16) |
| Diabetes mellitus | 5 (17) | 2 (4) |
| Autoimmune disease | 4 (13) | 2 (4) |
Abbreviations: eGFR, estimated glomerular filtration rate; GERD, gastroesophageal reflux disease; LVH, left ventricular hypertrophy; MDI‐HTN, multiple drug intolerances to antihypertensive medication; sCr, serum creatinine; TC:HDL, total cholesterol:high‐density lipoprotein cholesterol.